Lillie James Woodruff 4

What Happened
Lillie James Woodruff, Chief Scientific Officer of MapLight Therapeutics (MPLT), sold a total of 51,707 shares in open-market transactions between May 4 and May 6, 2026 for aggregate proceeds of about $1,468,252. Sales by date:

• May 4, 2026 — 15,801 shares (9,250 @ $27.50; 5,526 @ $28.37; 320 @ $29.56; 705 @ $30.08) — $441,813 total.
• May 5, 2026 — 11,095 shares (10,132 @ $28.12; 963 @ $29.00) — $312,839 total.
• May 6, 2026 — 24,811 shares (8,390 @ $28.04; 16,421 @ $29.13) — $713,600 total.
  All transactions are coded “S” (sale). Sales are generally routine liquidity events and do not by themselves indicate company prospects.

Key Details

• Transaction dates: May 4–6, 2026; Form 4 filed May 6, 2026 (appears timely—within typical 2‑business‑day reporting window).
• Total shares sold: 51,707; total proceeds: ~$1.47 million.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Notable footnotes: F1 indicates one or more trades were made pursuant to a Rule 10b5‑1 trading plan adopted Dec 29, 2025. Footnotes F2–F9 note that reported prices are weighted averages across multiple execution prices (ranges provided) and that the filer can supply per‑price detail on request.
• Transaction code: S = Sale (no purchases, exercises, or awards reported here).

Context

• A Rule 10b5‑1 plan means some trades were pre‑scheduled under an approved plan (helps show trades were pre‑arranged, not necessarily based on inside information).
• Sales are common for personal liquidity, tax or diversification reasons; purchases are typically seen as a stronger signal of insider confidence.
• This summary is factual and does not speculate on the insider’s motives. If you need the exact per‑trade execution prices within the weighted averages, the filer has offered to provide that breakdown on request.